RxDoctor Payments Data

Lauren Holloway, PA

Physician Assistant · Tulsa, OKNPI 1184181026

Payments from drug & device makers

$2,486in general payments, 2019–2025

Across 100 payments — averaging $24.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$802
  • Urogen Pharma, Inc.$327
  • Sumitomo Pharma America, Inc.$184
  • Coloplast$178
  • Astellas Pharma US Inc$160
  • Endo Pharmaceuticals Inc.$121
  • plus $715 from 17 others

What the payments were for

  • Travel & lodging$28111%
  • Food & beverage$2,13586%
  • Education$703%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,486 in reported general payments places this provider in the 80th percentile of 1,491 physician assistant providers in Oklahoma.

See all physician assistant providers in Oklahoma

Medicare billing

Part B allowed, 2024
$17,368
Medicare patients
139
Services billed
490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron219$163,990
MyrbetriqMirabegron238$161,978
Solifenacin Succinate636$20,982
Estradiol266$17,340
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst339$6,717
Fesoterodine Fumarate ErFesoterodine Fumarate32$3,794
Tolterodine Tartrate ErTolterodine Tartrate36$2,957
Tamsulosin Hcl275$2,275
Trimethoprim43$2,180
Tolterodine Tartrate28$1,882
Trospium Chloride42$1,713
Potassium Citrate ErPotassium Citrate34$1,540
Cephalexin187$1,535
NitrofurantoinNitrofurantoin Macrocrystal37$1,397
Methenamine Hippurate36$1,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$184$163,990219 claims
Astellas Pharma US IncMyrbetriq$160$161,978238 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,491 physician assistant providers in Oklahoma.

Other physician assistant in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →